Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
If you look at the sales revenue for the Oct-Dec 2020 quarter against the Jan-March 2021 quarter...on a "like for like" basis ....then the sales revenues look like they are the same quarter on quarter
Oct - Dec 2020 - AUS $ 456,000 *
Jan-March 2021 - AUS $ 455,000 ** ($880,000-$425,000)
* https://mgcpharma.com.au/wp-content/uploads/2021/02/December-Quarterly-Activity-and-Cashflow-Report.pdf
** https://wcsecure.weblink.com.au/pdf/MXC/02361107.pdf
"like for like basis" - removing the effect of the SPC Initial Purchase to ensure equal comparison
The sales growth is cumulative it’s not a real reflection
Some very poorly educated investors on here just stick to the greyhounds or your 50p footy accumulator
Soooo what you're saying is MOOOOON ?
Change of tone Irontoy? Don't buy anymore?
Don't give these idiots the time of day, they deserve zero attention. Utter horse manure!
Totally agree. You all should accumulate as many shares as possible.
Jamie well said, most are adding to their portfolio and waiting for the master plan to materialise... GLA
Lol, thought I would have a browse on here after a while off and I must say, there’s a small group of the people on here that are grown adults and act like 5 year olds. I get the game, ramping, de-ramping, I don’t agree for one but if those are the childish games people want to play that’s fine.
Onto the interesting stuff, record revenue’s released on Wednesday followed by a poor RNS on Thursday which make have been taken out of hand more than it should have been. Today’s presentation is also another highlighter about what this share is about, the intentions and the team behind the hopeful ‘master plan’. I reiterate that once/if Artermic/Cimetra (I don’t know wether I’m coming or going) passes phase III then we are really looking at a product that could change the landscape of the company. Note the ‘Financial Year Cumulative Phytocannabinoid Product Growth‘ in the slideshow showed the figures which doesn’t include sales of Artemic. Doesn’t take much to find out where this is heading if it passes phase III.
As always DYOR and GLA, but one last thing and probably most importantly. Don’t give these people who come on here and de-ramp the **** out of stocks the time of day, you get 1 life so don’t spend precious time wasting it on these individuals.
Cheers
Jamie